295 related articles for article (PubMed ID: 1312196)
1. Differential regulation of striatal preproenkephalin mRNA by D1 and D2 dopamine receptors.
Pollack AE; Wooten GF
Brain Res Mol Brain Res; 1992 Jan; 12(1-3):111-9. PubMed ID: 1312196
[TBL] [Abstract][Full Text] [Related]
2. D2 dopaminergic regulation of striatal preproenkephalin mRNA levels is mediated at least in part through cholinergic interneurons.
Pollack AE; Wooten GF
Brain Res Mol Brain Res; 1992 Mar; 13(1-2):35-41. PubMed ID: 1315917
[TBL] [Abstract][Full Text] [Related]
3. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
4. Role of a 35 kDa fos-related antigen (FRA) in the long-term induction of striatal dynorphin expression in the 6-hydroxydopamine lesioned rat.
Bronstein DM; Ye H; Pennypacker KR; Hudson PM; Hong JS
Brain Res Mol Brain Res; 1994 May; 23(3):191-203. PubMed ID: 7914658
[TBL] [Abstract][Full Text] [Related]
5. Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation.
Hu XT; Wachtel SR; Galloway MP; White FJ
J Neurosci; 1990 Jul; 10(7):2318-29. PubMed ID: 1973947
[TBL] [Abstract][Full Text] [Related]
6. Nigral D1 and striatal D2 receptors mediate the behavioral effects of dopamine agonists.
LaHoste GJ; Marshall JF
Behav Brain Res; 1990 May; 38(3):233-42. PubMed ID: 1973041
[TBL] [Abstract][Full Text] [Related]
7. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses.
Weick BG; Walters JR
Brain Res; 1987 Mar; 405(2):234-46. PubMed ID: 2952219
[TBL] [Abstract][Full Text] [Related]
8. Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes.
Jiang HK; McGinty JF; Hong JS
Brain Res; 1990 Jan; 507(1):57-64. PubMed ID: 1967976
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists.
Morissette M; Grondin R; Goulet M; Bédard PJ; Di Paolo T
J Neurochem; 1999 Feb; 72(2):682-92. PubMed ID: 9930741
[TBL] [Abstract][Full Text] [Related]
10. D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease.
Paul ML; Graybiel AM; David JC; Robertson HA
J Neurosci; 1992 Oct; 12(10):3729-42. PubMed ID: 1357113
[TBL] [Abstract][Full Text] [Related]
11. Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion.
Granata R; Wenning GK; Jolkkonen J; Jenner P; Marsden CD
J Neural Transm (Vienna); 1996; 103(3):249-60. PubMed ID: 8739837
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding.
Engber TM; Marin C; Susel Z; Chase TN
Eur J Pharmacol; 1993 Jun; 236(3):385-93. PubMed ID: 8102970
[TBL] [Abstract][Full Text] [Related]
13. N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion.
Engber TM; Anderson JJ; Boldry RC; Kuo S; Chase TN
Neuroscience; 1993 Jun; 54(4):1051-61. PubMed ID: 8101981
[TBL] [Abstract][Full Text] [Related]
14. Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum.
Chen JF; Aloyo VJ; Weiss B
Neuroscience; 1993 Jun; 54(3):669-80. PubMed ID: 8101360
[TBL] [Abstract][Full Text] [Related]
15. Repeated stimulation of D1 dopamine receptors causes time-dependent alterations in the sensitivity of both D1 and D2 dopamine receptors within the rat striatum.
Hu XT; Brooderson RJ; White FJ
Neuroscience; 1992 Sep; 50(1):137-47. PubMed ID: 1357592
[TBL] [Abstract][Full Text] [Related]
16. Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats.
Pollack AE; Yates TM
Neuroscience; 1999; 94(2):505-14. PubMed ID: 10579212
[TBL] [Abstract][Full Text] [Related]
17. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
LaHoste GJ; Marshall JF
Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
[TBL] [Abstract][Full Text] [Related]
18. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
[TBL] [Abstract][Full Text] [Related]
19. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Sonsalla PK; Manzino L; Heikkila RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
[TBL] [Abstract][Full Text] [Related]
20. Neonatal and adult 6-hydroxydopamine-induced lesions differentially alter tachykinin and enkephalin gene expression.
Sivam SP; Breese GR; Krause JE; Napier TC; Mueller RA; Hong JS
J Neurochem; 1987 Nov; 49(5):1623-33. PubMed ID: 2889804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
